Thinking of joining a study?

Register your interest

NCT05552586 | Not yet recruiting | Coronary Artery Bypass Grafting


Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
Sponsor:

Ain Shams University

Information provided by (Responsible Party):

eman ahmed el-said casper

Brief Summary:

The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.

Condition or disease

Coronary Artery Bypass Grafting

Coronary Artery Disease

Intervention/treatment

Melatonin

placebo

Phase

Not Applicable

Detailed Description:

Myocardial ischemia is a situation where there is an inadequate blood and oxygen supply to the heart muscles due to partial or complete obstruction of the coronary arteries, predisposing the affected cardiac muscle to death. Hence, restoration of blood supply is critical to reestablish myocardial reperfusion. The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Strategies to improve the CABG related complications are much needed to augment the positive outcomes in the post-operative surviving patients. There are various therapeutic approaches to decrease or ameliorate myocardial I/R injury, these include reperfusion controlling, cardioprotective events and management via various interventions. Melatonin (N-acetyl 5-methoxy-tryptamine) is mainly secreted by the pineal gland to regulate sleep. Since 1993 when melatonin was first reported, a wide range of melatonin functions have been directly confirmed by multiple scientific studies . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. Early studies have shown that melatonin exerts beneficial effects in the context of renal I/R, myocardial I/R, and hepatic I/R. The ability to protect against I/R injury may relate to the functions of melatonin as both an anti-inflammatory and an antioxidant agent . Some authors show an anti-apoptotic action of melatonin in different organs of the body, such as thymus, kidney, brain and liver . the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.}}

Study Type : Interventional
Estimated Enrollment : 22 participants
Masking : Triple
Primary Purpose : Treatment
Official Title : The Effect of Melatonin on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
Actual Study Start Date : October 2022
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : September 2023
Arm Intervention/treatment

Active Comparator: Melatonin group

Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.

Dietary Supplement: Melatonin

Placebo Comparator: Control group

Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.

Other: placebo

Ages Eligible for Study: 30 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Patients who will undergo elective CABG,
  • ready to participate in the study and
  • can be reached by phone
Exclusion Criteria
  • • Patients who will require urgent surgery and won't have adequate time to take medications for 5 days,
  • Re-operative patients (CABG),
  • Off-pump CABG,
  • Patients who have concomitant renal failure,
  • Patients with severe respiratory problems.
  • Patients with previous stroke or significant cerebrovascular disease,
  • Patients with hepatitis b,c and HIV.
  • Inflammatory disease ex. Rheumatoid arthritis, psoriasis…,
  • Patients with ejection fraction (EF%) lower than 40%,
  • Patients undergo CABG surgery with simultaneous heart valve repair or replacement, resection of a ventricular aneurysm, or other operations.
  • Pregnancy and lactation.

Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery

Location Details


Please Choose a site



Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Loading...